Effects of acute and chronic treatment with magnesium in the forced swim test in rats

Pharmacological Reports

Volumn 57, Issue 5, 2005, Pages 654-658

  Poleszak, Ewa ^a   Wlaź, Piotr ^b   Kedzierska, Ewa ^a   Radziwon Zaleska, Maria ^e   Pilc, Andrzej ^c,d   Fidecka, Sylwia ^a   Nowak, Gabriel ^c,d  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Depression; Forced swim test; Magnesium; NMDA receptor; Rats

Indexed keywords

MAGNESIUM CHLORIDE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TOLERANCE; FORCED SWIMMING TEST; IMMOBILIZATION; LONG TERM CARE; NONHUMAN; PROVOCATION TEST; RAT;

EID: 33646201594     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Berman RM, Capiello A, Anand A, Oren DA, Heninger GR, Cherney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 1999, 47, 351-354.
2. Decollogne S, Tomas A, Lecerf C, Adamowicz E, Seman M: NMDA receptor complex blockade by oral administration of magnesium: comparison with MK-801. Pharmacol Biochem Behav, 1997, 58, 261-268.
3. Frizel D, Coppen A, Marks V: Plasma magnesium and calcium in depression. Br J Psychiatry, 1969, 115, 1375-1377.
4. Hashizume N, Mori M: An analysis of hypermagnesemia and hypomagnesemia. Jap J Med, 1990, 29, 368-372.
5. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S.: Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Res, 1999, 3, 239-246.
6. Henrotte JG, Franck G, Santarromana M, Frances H, Mouton D, Motta R: Mice selected for low and high blood magnesium levels: a new model of stress studies. Physiol Behav, 1997, 61, 653-658.
7. Hollister LE, Csernansky JG: Clinical Pharmacology of Psychotherapeutic Drugs, 3rd edn., Churchill Livingstone, New York, 1990.
8. Hulanicki A: Magnesium: chemical properties and methods of determination. Clin Chem Enzym Commun, 1993, 5, 135-142.
9. Kantak KM: Magnesium deficiency alters aggressive behavior and catecholamine function. Behav Neurosci, 1988, 102, 304-311.
10. Kroczka B, Branski P, Palucha A, Pilc A, Nowak G: Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull, 2001, 55, 297-300.
11. Kroczka B, Zieba A, Dudek D, Pilc A, Nowak G: Zinc exhibits an antidepressant-like effects in the forced swiming test in mice. Pol J Pharmacol, 2000, 52, 403-406.
12. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyer R: Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammantory response in that illness. Biol Psychiatry, 1997, 42, 349-358.
13. 2+ -block site of the NMDA receptor channel. Nature, 1992, 358, 673-675.
14. Murck H: Magnesium and affective disorders. Nutr Neurosci, 2002, 5, 375-389.
15. Novak L, Bregestowski P, Acher P, Herbert A, Prochiantz A: Magnesium gates glutamate-activated channels in mouse central neurons. Nature, 1984, 307, 462-465.
16. Nowak G, Siwek M, Dudek D, Zieba A, Pilc A: Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol, 2003, 55, 1143-1147.
17. Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, Sadlik K, Piekoszewski W: Antidepressantlike effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull, 2003, 61, 159-164.
18. Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA: Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-amino-cyclopropanecarboxylic acid. J Pharmacol Exp Ther, 1993, 265, 1380-1386.
19. Nowak G, Zieba A, Dudek D, Krośniak M, Szymaczek M, Schlegel-Zawadzka M: Serum trace elements in animal models and human depression. Part I. Zinc. Hum. Psychopharmacol Clin Exp, 1999, 14, 83-86.
20. Oswald I, Brezinova V, Dunleavy DLF: On the slowness of action of tricyclic antidepressant drugs. Br J Psychiatry, 1972, 120, 673-677.
21. Poleszak E, Szewczyk B, Kedzierska E, Wlaź P, Pilc A, Nowak G: Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav, 2004, 78, 7-12.
22. Porsolt RD, Anton G, Blavet N: Behavioral despair in rat: A new model sensitive to antidepressant treatments. Eur J Pharmacol, 1978, 47, 379-391.
23. Rasmussen HH, Mortensen PB, Jensen IW: Depression and magnesium deficiency. Inter J Psychiat Med, 1989, 19, 57-63.
24. Ryan MF: The role of magnesium in clinical biochemistry: an overview, Ann Clin Biochem, 1991, 28, 19-26.
25. Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol, 1999, 375, 31-40.
26. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R: Adaptation of N-methyl-D-aspartate receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry, 1996, 29, 23-26.
27. Skolnick P, Legutko B, Li X, Bymaster FP: Current perspectives on the development of non-biogenic amine-based antidepressants. Pharmacol Res, 2001, 43, 411-422.
28. Szewczyk B, Brański P, Wierońska JM, Pałucha A, Pilc A, Nowak G: Interaction of zinc with antidepressants in the forced swimming test in mice. Pol J Pharmacol, 2002, 54, 681-685.
29. Widmer J, Henrotte JG, Raffin Y, Bovier P, Hillert H, Gaillard JM: Relationship between erytrocyte magnesium, plasma electrolytes and cortisol and intensity of symptoms in major depressed patients. J Affect Disord, 1995, 34, 201-209.
30. Zieba A, Kata R, Dudek D, Schlegel-Zawadzka M, Nowak G: Serum trace elements in animal models and human depression: Part III. Magnesium. Relationship with Copper. Hum Psychopharmacol Clin Exp, 2000, 15, 631-635.